These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 28765246)

  • 21. Consensus of the definitions of the OMERACT glucocorticoid impact core domain set for people with rheumatic and musculoskeletal diseases.
    Lyne SA; Yip K; Vasiliou VS; Katz DA; Richards P; Tieu J; Black RJ; Bridgewater S; Palmowski A; Beaton D; Maxwell LJ; Robson JC; Mackie SL; Goodman SM; Hill CL
    Semin Arthritis Rheum; 2024 Feb; 64():152338. PubMed ID: 38134623
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identifying a Core Domain Set to Assess Psoriasis in Clinical Trials.
    Callis Duffin K; Merola JF; Christensen R; Latella J; Garg A; Gottlieb AB; Armstrong AW
    JAMA Dermatol; 2018 Oct; 154(10):1137-1144. PubMed ID: 29874367
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The ASAS-OMERACT core domain set for axial spondyloarthritis.
    Navarro-Compán V; Boel A; Boonen A; Mease P; Landewé R; Kiltz U; Dougados M; Baraliakos X; Bautista-Molano W; Carlier H; Chiowchanwisawakit P; Dagfinrud H; de Peyrecave N; El-Zorkany B; Fallon L; Gaffney K; Garrido-Cumbrera M; Gensler LS; Haroon N; Kwan YH; Machado PM; Maksymowych WP; Poddubnyy D; Protopopov M; Ramiro S; Shea B; Song IH; van Weely S; van der Heijde D
    Semin Arthritis Rheum; 2021 Dec; 51(6):1342-1349. PubMed ID: 34489113
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Patient Endorsement of the Outcome Measures in Rheumatology (OMERACT) Total Joint Replacement (TJR) clinical trial draft core domain set.
    Singh JA; Dowsey M; Choong PF
    BMC Musculoskelet Disord; 2017 Mar; 18(1):111. PubMed ID: 28298194
    [TBL] [Abstract][Full Text] [Related]  

  • 25. OMERACT 2018 Modified Patient-reported Outcome Domain Core Set in the Life Impact Area for Adult Idiopathic Inflammatory Myopathies.
    Regardt M; Mecoli CA; Park JK; de Groot I; Sarver C; Needham M; de Visser M; Shea B; Bingham CO; Lundberg IE; Song YW; Christopher-Stine L; Alexanderson H
    J Rheumatol; 2019 Oct; 46(10):1351-1354. PubMed ID: 30770504
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Content and Face Validity and Feasibility of 5 Candidate Instruments for Psoriatic Arthritis Randomized Controlled Trials: The PsA OMERACT Core Set Workshop at the GRAPPA 2017 Annual Meeting.
    Holland R; Tillett W; Ogdie A; Leung YY; Gladman DD; Callis Duffin K; Coates LC; Mease PJ; Eder L; Strand V; Elmamoun M; Højgaard P; Chau J; de Wit M; Goel N; Lindsay CA; FitzGerald O; Shea B; Beaton D; Orbai AM
    J Rheumatol Suppl; 2018 Jun; 94():17-25. PubMed ID: 29858348
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PsAID12 Provisionally Endorsed at OMERACT 2018 as Core Outcome Measure to Assess Psoriatic Arthritis-specific Health-related Quality of Life in Clinical Trials.
    Orbai AM; Holland R; Leung YY; Tillett W; Goel N; Christensen R; McHugh N; Gossec L; de Wit M; Højgaard P; Coates LC; Mease PJ; Birt J; Fallon L; FitzGerald O; Ogdie A; Shea B; Strand V; Duffin KC; Tugwell P; Beaton D; Gladman DD
    J Rheumatol; 2019 Aug; 46(8):990-995. PubMed ID: 30554154
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Instrument Selection Using the OMERACT Filter 2.1: The OMERACT Methodology.
    Beaton DE; Maxwell LJ; Shea BJ; Wells GA; Boers M; Grosskleg S; Bingham CO; Conaghan PG; D'Agostino MA; de Wit MP; Gossec L; March LM; Simon LS; Singh JA; Strand V; Tugwell P
    J Rheumatol; 2019 Aug; 46(8):1028-1035. PubMed ID: 30709952
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Assessing the effect of interventions for axial spondyloarthritis according to the endorsed ASAS/OMERACT core outcome set: a meta-research study of trials included in Cochrane reviews.
    Andreasen RA; Kristensen LE; Baraliakos X; Strand V; Mease PJ; de Wit M; Ellingsen T; Hansen IMJ; Kirkham J; Wells GA; Tugwell P; Maxwell L; Boers M; Egstrup K; Christensen R
    Arthritis Res Ther; 2020 Jul; 22(1):177. PubMed ID: 32711571
    [TBL] [Abstract][Full Text] [Related]  

  • 30. OMERACT Filter 2.1: Elaboration of the Conceptual Framework for Outcome Measurement in Health Intervention Studies.
    Boers M; Beaton DE; Shea BJ; Maxwell LJ; Bartlett SJ; Bingham CO; Conaghan PG; D'Agostino MA; de Wit MP; Gossec L; March L; Simon LS; Singh JA; Strand V; Wells GA; Tugwell P
    J Rheumatol; 2019 Aug; 46(8):1021-1027. PubMed ID: 30770515
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Enhanced Patient Involvement and the Need to Revise the Core Set - Report from the Psoriatic Arthritis Working Group at OMERACT 2014.
    Tillett W; Eder L; Goel N; De Wit M; Gladman DD; FitzGerald O; Campbell W; Helliwell PS; Gossec L; Orbai AM; Ogdie A; Strand V; McHugh NJ; Mease PJ
    J Rheumatol; 2015 Nov; 42(11):2198-203. PubMed ID: 25934828
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Endorsement of the OMERACT core domain set for shared decision making interventions in rheumatology trials: Results from a multi-stepped consensus-building approach.
    Toupin-April K; Décary S; de Wit M; Meara A; Barton JL; Fraenkel L; Li LC; Brooks P; Shea B; Stacey D; Légaré F; Lydiatt A; Hofstetter C; Proulx L; Christensen R; Voshaar M; Suarez-Almazor ME; Boonen A; Meade T; March L; Jull JE; Campbell W; Alten R; Morgan EM; Kelly A; Kaufman J; Hill S; Maxwell LJ; Guillemin F; Beaton D; El-Miedany Y; Mittoo S; Westrich Robertson T; Bartlett SJ; Singh JA; Mannion M; Nasef SI; de Souza S; Boel A; Adebajo A; Arnaud L; Gill TK; Moholt E; Burt J; Jayatilleke A; Hmamouchi I; Carrott D; Blanco FJ; Mather K; Maharaj A; Sharma S; Caso F; Fong C; Fernandez AP; Mackie S; Nikiphorou E; Jones A; Greer-Smith R; Sloan VS; Akpabio A; Strand V; Umaefulam V; Monti S; Melburn C; Abaza N; Schultz K; Stones S; Kiwalkar S; Srinivasalu H; Constien D; King LK; Tugwell P
    Semin Arthritis Rheum; 2021 Jun; 51(3):593-600. PubMed ID: 33892937
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identifying Possible Outcome Domains from Existing Outcome Measures to Inform an OMERACT Core Domain Set for Safety in Rheumatology Trials.
    Klokker L; Berthelsen DB; Woodworth T; Andersen KM; Furst DE; Devoe D; Williamson PR; Suarez-Almazor ME; Strand V; Leong AL; Goel N; Boers M; Brooks PM; March L; Sloan VS; Tugwell P; Simon LS; Christensen R
    J Rheumatol; 2019 Sep; 46(9):1173-1178. PubMed ID: 31043547
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Outcome Domains and Measures in Total Joint Replacement Clinical Trials: Can We Harmonize Them? An OMERACT Collaborative Initiative.
    Singh JA; Dohm M; Sprowson AP; Wall PD; Richards BL; Gossec L; Hawker GA; Riddle DL; Buchbinder R
    J Rheumatol; 2015 Dec; 42(12):2496-502. PubMed ID: 25834208
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evidence for Updating the Core Domain Set of Outcome Measures for Juvenile Idiopathic Arthritis: Report from a Special Interest Group at OMERACT 2016.
    Morgan EM; Riebschleger MP; Horonjeff J; Consolaro A; Munro JE; Thornhill S; Beukelman T; Brunner HI; Creek EL; Harris JG; Horton DB; Lovell DJ; Mannion ML; Olson JC; Rahimi H; Gallo MC; Calandra S; Ravelli A; Ringold S; Shenoi S; Stinson J; Toupin-April K; Strand V; Bingham CO
    J Rheumatol; 2017 Dec; 44(12):1884-1888. PubMed ID: 28811355
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Update on treatment of polymyalgia rheumatica.
    Camellino D; Dejaco C
    Reumatismo; 2018 Mar; 70(1):59-66. PubMed ID: 29589404
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Defining domains: developing consensus-based definitions for foundational domains in OMERACT core outcome sets.
    Maxwell LJ; Jones C; Bingham CO; Boers M; Boonen A; Choy E; Christensen R; Conaghan PG; D'Agostino MA; Doria AS; Grosskleg S; Hill CL; Hofstetter C; Horgan B; Kroon F; Leung YY; Mackie S; Meara A; Shea BJ; Simon LS; Touma Z; Tugwell P; Wells GA; Beaton DE
    Semin Arthritis Rheum; 2024 Jun; 66():152423. PubMed ID: 38460282
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Patient-reported outcomes in polymyalgia rheumatica.
    Matteson EL; Maradit-Kremers H; Cimmino MA; Schmidt WA; Schirmer M; Salvarani C; Bachta A; Dejaco C; Duftner C; Slott Jensen H; Poór G; Kaposi NP; Mandl P; Balint PV; Schmidt Z; Iagnocco A; Cantini F; Nannini C; Macchioni P; Pipitone N; Del Amo M; Espígol-Frigolé G; Cid MC; Martínez-Taboada VM; Nordborg E; Direskeneli H; Aydin SZ; Ahmed K; Hazelman B; Pease C; Wakefield RJ; Luqmani R; Abril A; Marcus R; Gonter NJ; Maz M; Crowson CS; Dasgupta B
    J Rheumatol; 2012 Apr; 39(4):795-803. PubMed ID: 22422492
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Polymyalgia rheumatica-like syndrome from checkpoint inhibitor therapy: case series and systematic review of the literature.
    Calabrese C; Cappelli LC; Kostine M; Kirchner E; Braaten T; Calabrese L
    RMD Open; 2019; 5(1):e000906. PubMed ID: 31168414
    [TBL] [Abstract][Full Text] [Related]  

  • 40. OMERACT Development of a Core Domain Set of Outcomes for Shared Decision-making Interventions.
    Toupin-April K; Barton JL; Fraenkel L; Meara A; Li LC; Brooks P; de Wit M; Stacey D; Légaré F; Shea B; Lyddiatt A; Hofstetter C; Christensen R; Scholte Voshaar M; Suarez-Almazor ME; Boonen A; Meade T; March L; Jull JE; Campbell W; Alten R; Karuranga S; Morgan EM; Kelly A; Kaufman J; Hill S; Maxwell LJ; Beaton D; El-Miedany Y; Mittoo S; Bartlett SJ; Singh JA; Tugwell PS
    J Rheumatol; 2019 Oct; 46(10):1409-1414. PubMed ID: 30709963
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.